Question:
Secukinumab (Consentyx)
Author: Natalia AbesadaAnswer:
Anti IL-17A Ind: psoriasis en plaques modéré a sevre EI: risque accru de cancer et d'infection (+EI du anti TNF alpha)
0 / 5 (0 ratings)
1 answer(s) in total
Author
Natalia Abesada
Answer:
0 / 5 (0 ratings)
1 answer(s) in total